Clinical Trial Update: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older [Phase 2]

View source ↗

Summary

Phase 2 trial of Janssen's Ad26.RSV.preF-based vaccine regimen for preventing RSV-mediated lower respiratory tract disease in adults aged 65 and older was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF vaccine (Adenovirus 26 vector-based RSV pre-F protein vaccine)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Viruses, Respiratory Tract Diseases | Phase 2 | Status: TERMINATED | Results posted: 2023-07-24